34 Results

People

  1. Lesokhin
    Lesokhin
  2. Usmani
    Usmani
  3. Hassoun
    Hassoun
  4. Hultcrantz
    Hultcrantz
  5. Korde
    Korde
  6. Shah
    Shah
  7. Mailankody
    Mailankody
  8. Giralt
    Giralt
  9. Lahoud
    Lahoud
  10. Postow
    Postow

Groups

  1. Center for Hematologic Malignancies (34)
  2. Department of Medicine (34)
  3. Hematologic Malignancies Research (34)
  4. Hematologic Malignancies, Division of (34)
  5. Myeloma (34)
  6. CTCR Scholars (10)
  7. Sloan Kettering Institute Postdocs (8)
  8. Solid Tumor Oncology Division (8)
  9. Survivorship Research (8)
  10. Biostatistics Service (7)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Alexander Lesokhin"
  4. "American Society of Clinical Oncology"
Formats
  1. Meeting Abstract (30)
  2. Journal Article (4)
Groups
  1. Center for Hematologic Malignancies (34)
  2. Department of Medicine (34)
  3. Hematologic Malignancies Research (34)
  4. Hematologic Malignancies, Division of (34)
  5. Myeloma (34)
  6. CTCR Scholars (10)

More Groups

People
  1. Alexander Lesokhin (34)
  2. Saad Usmani (10)
  3. Hani Hassoun (8)
  4. Malin Hultcrantz (8)
  5. Neha Korde (8)
  6. Urvi Shah (8)

More People

Years
  1. 2023 (11)
  2. 2022 (8)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (3)
  6. 2018 (1)

More Years

Publications
  1. Journal of Clinical Oncology (34)
Publishers
  1. American Society of Clinical Oncology (34)

Results (34)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent
    Meeting Abstract

    Kumar, S.; Bachier, C. R.; Cavo, M.; Corradini, P.; Delforge, M.; Janowski, W.; Lesokhin, A. M.; Mina, R.; Paris, L.; Rosiñol, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Risk of MGUS, a multiple myeloma precursor, in relation to food and beverage intake in the National Health and Nutrition Examination Survey (NHANES)
    Meeting Abstract

    Joseph, J.; Tang, L.; Hillengass, J.; Landgren, O.; Usmani, S. Z.; Lesokhin, A. M.; Moysich, K. B.; Shah, U. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1
    Meeting Abstract

    Tomasson, M. H.; Bahlis, N. J.; Costello, C.; Raje, N. S.; Levy, M. Y.; Dholaria, B. R.; Solh, M. M.; Damore, M. A.; Jiang, S.; Xie, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP cohort
    Meeting Abstract

    Parikh, R.; Castro, F.; Eustaquio, J. C.; Derkach, A.; Joseph, J.; Lesokhin, A. M.; Usmani, S. Z.; Shah, U. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raje, N. S.; Leleu, X. P.; Lesokhin, A. M.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; Manier, S.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies
    Meeting Abstract

    Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant
    Meeting Abstract

    Shah, G. L.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D. J.; Gupta, G. K.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martinez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Lin, Y.; Martin, T. G.; Usmani, S. Z.; Berdeja, J. G.; Jakubowiak, A. J.; Agha, M. E.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies
    Meeting Abstract

    Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky Yanovsky, A.; Leleu, X. P.; Karlin, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save